Feasibility of Novel Diagnostics for TB
in Endemic Countries
Analytic core lab rutgers
Moldova
peru
south africa
Uganda
vietnam
Mission
To support the evaluation of early-stage TB diagnostics & novel diagnostic strategies in the context of existing clinical algorithms in TB endemic countries.
FEND for TB will perform proof-of-principle studies of novel diagnostics & strategies and provide feedback to diagnostic developers on the performance of the technologies and their most effective use in endemic settings.
About
The primary purpose of the FEND for TB Consortium is to evaluate early stage diagnostics and novel diagnostic strategies for tuberculosis in the context of existing clinical algorithms in TB endemic countries.
connect@fend-tb.org
Collaborators
Protocols
The Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) Consortium, funded by the U.S. National Institutes of Health, is comprised of a group of international clinical and laboratory investigators with the primary purpose of supporting the evaluation of early-stage tuberculosis diagnostic assays and strategies in the context of existing clinical algorithms in tuberculosis endemic countries.
Adult
Pediatric
Drug Resistant
For Manufacturers
FEND mission is to support the evaluation of early-stage TB diagnostics & novel diagnostic strategies in the context of existing clinical algorithms in TB endemic countries.
FEND for TB will perform proof-of-principle studies of novel diagnostics & strategies and provide feedback to diagnostic developers on the performance of the technologies and their most effective use in endemic settings.
Support
Research on this website (FEND-TB.org) was supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Number U01AI152084. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.